hrcak mascot   Srce   HID

Biochemia Medica, Vol.28 No.1 Veljača 2018.

Izvorni znanstveni članak
https://doi.org/10.11613/BM.2018.010706

Diagnostic value of tumour markers in pleural effusions

Darian Volarić   ORCID icon orcid.org/0000-0001-5702-4749 ; Division of Pulmonology, Clinic of Internal Medicine, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Department of Internal Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
Veljko Flego   ORCID icon orcid.org/0000-0002-6333-9883 ; Division of Pulmonology, Clinic of Internal Medicine, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Department of Internal Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
Gordana Žauhar   ORCID icon orcid.org/0000-0002-5931-2872 ; Department of Medical Physics and Biophysics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; Department of Physics, University of Rijeka, Rijeka, Croatia
Ljiljana Bulat-Kardum ; Division of Pulmonology, Clinic of Internal Medicine, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Department of Internal Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Puni tekst: engleski, pdf (1019 KB) str. 1-11 preuzimanja: 27* citiraj
APA 6th Edition
Volarić, D., Flego, V., Žauhar, G. i Bulat-Kardum, Lj. (2018). Diagnostic value of tumour markers in pleural effusions. Biochemia Medica, 28 (1), 1-11. https://doi.org/10.11613/BM.2018.010706
MLA 8th Edition
Volarić, Darian, et al. "Diagnostic value of tumour markers in pleural effusions." Biochemia Medica, vol. 28, br. 1, 2018, str. 1-11. https://doi.org/10.11613/BM.2018.010706. Citirano 26.09.2018.
Chicago 17th Edition
Volarić, Darian, Veljko Flego, Gordana Žauhar i Ljiljana Bulat-Kardum. "Diagnostic value of tumour markers in pleural effusions." Biochemia Medica 28, br. 1 (2018): 1-11. https://doi.org/10.11613/BM.2018.010706
Harvard
Volarić, D., et al. (2018). 'Diagnostic value of tumour markers in pleural effusions', Biochemia Medica, 28(1), str. 1-11. doi: https://doi.org/10.11613/BM.2018.010706
Vancouver
Volarić D, Flego V, Žauhar G, Bulat-Kardum Lj. Diagnostic value of tumour markers in pleural effusions. Biochemia Medica [Internet]. 15.02.2018. [pristupljeno 26.09.2018.];28(1):1-11. doi: https://doi.org/10.11613/BM.2018.010706
IEEE
D. Volarić, V. Flego, G. Žauhar i Lj. Bulat-Kardum, "Diagnostic value of tumour markers in pleural effusions", Biochemia Medica, vol.28, br. 1, str. 1-11, veljača 2018. [Online]. doi: https://doi.org/10.11613/BM.2018.010706

Rad u XML formatu

Sažetak
Introduction: We investigated whether tumour markers carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA-
125), and cytokeratin 19 fragment (CYFRA 21-1) in pleural effusions and serum can be used to distinguish pleural effusion aetiology.
Materials and methods: During the first thoracentesis, we measured pleural fluid and serum tumour marker concentrations and calculated the
pleural fluid/serum ratio for patients diagnosed with pleural effusion, using electrochemiluminescence immunoassays. Receiver operating characteristic
(ROC) analysis was carried out and the Hanley and McNeil method was used to test the significance of the difference between the areas under
ROC curves (AUCs). In order to detect which tumour marker best discriminates between malignant and non-malignant pleural effusions and to establish
the predictive value of those markers, discriminant function analysis (DFA) and logistic regression analysis were utilized.
Results: Serum tumour markers CYFRA 21-1 and NSE as well as pleural NSE were good predictors of pleural effusion malignancy and their combined
model was found statistically significant (Chi-square = 28.415, P < 0.001). Respective ROC analysis showed significant discrimination value of the
combination of these three markers (AUC = 0.79).
Conclusions: Serum markers showed superiority to pleural fluid markers in determining pleural fluid aetiology. Serum CYFRA 21-1 and NSE concentrations
as well as pleural fluid NSE values had the highest clinical value in differentiating between malignant and non-malignant pleural effusions.
The combination of these three markers produced a significant model to resolve pleural effusion aetiology.

Ključne riječi
Key words: pleural effusion; CA-125 antigen; carcinoembryonic antigen; neuron-specific enolase; cytokeratin 19 fragment

Hrčak ID: 192381

URI
https://hrcak.srce.hr/192381

Reference

1 

Trapé J, Sant F, Franquesa J, Montesinos J, Arnau A, Sala M, et al. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. Respir Res. 2017;18:103. DOI: http://dx.doi.org/10.1186/s12931-017-0582-1 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/28545517

2 

Ferreiro L, Toubes ME, Valdés L. Contribution of pleural fluid analysis to the diagnosis of pleural effusion. Med Clin (Barc). 2015;145:171–7. DOI: http://dx.doi.org/10.1016/j.medcli.2014.08.005 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25433793

3 

Thomas R, Lee YC. Causes and management of common benign pleural effusions. Thorac Surg Clin. 2013;23:25–42. DOI: http://dx.doi.org/10.1016/j.thorsurg.2012.10.004 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23206715

4 

Gu Y, Zhai K, Shi HZ. Clinical value of tumor markers for determining cause of pleural effusion. Chin Med J (Engl). 2016;129:253–8. DOI: http://dx.doi.org/10.4103/0366-6999.174501 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26831224

5 

Ahadi M, Tehranian S, Memar B, Vossoughinia H, Salari M, Eskandari E, et al. Diagnostic value of carcinoembryonic antigen in malignancy-related ascites: systematic review and meta-analysis. Acta Gastroenterol Belg. 2014;77:418–24. PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25682632

6 

Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63:35–41. DOI: http://dx.doi.org/10.1136/thx.2007.077958 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/17573438

7 

Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;12:CD011134. DOI: http://dx.doi.org/10.1002/14651858.CD011134.pub2 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26661580

8 

Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. Int J Surg. 2016;25:134–44. DOI: http://dx.doi.org/10.1016/j.ijsu.2015.11.065 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26700203

9 

Light RW. The Light Criteria: the beginning and why they are useful 40 years later. Clin Chest Med. 2013;34:21–6. DOI: http://dx.doi.org/10.1016/j.ccm.2012.11.006 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23411053

10 

Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions – a biochemical approach. Biochem Med (Zagreb). 2014;24:123–37. DOI: http://dx.doi.org/10.11613/BM.2014.014 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24627721

11 

Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25:189–98. DOI: http://dx.doi.org/10.1183/16000617.0019-2016 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27246596

12 

Kim CH, Lee SY, Lee YD, Yoo SS, Lee SY, Cha SI, et al. Atypical pleural fluid profiles in tuberculous pleural effusion: Sequential changes compared with parapneumonic and malignant pleural effusions. Intern Med. 2016;55:1713–9. DOI: http://dx.doi.org/10.2169/internalmedicine.55.5803 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27374670

13 

Ma H, Bandos A, Gur D. On the use of partial area under the ROC curve for comparison of two diagnostic tests. Biom J. 2015;57:304–20. DOI: http://dx.doi.org/10.1002/bimj.201400023 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25537143

14 

Carter JV, Pan J, Rai S, Galandiuk S. ROC-ing along: Evaluation and interpretation of receiver operating characteristic curves. Surgery. 2016;159:1638–45. DOI: http://dx.doi.org/10.1016/j.surg.2015.12.029 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26962006

15 

Nguyen AH, Miller EJ, Wichman CS, Berim IG, Agrawal DK. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res. 2015;166:432–9. DOI: http://dx.doi.org/10.1016/j.trsl.2015.04.006 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25953662

16 

Korczynski P, Krenke R, Safianowska A, Gorska K, Abou Chaz MB, Maskey-Warzechowska M, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res. 2009;14:128–33. DOI: http://dx.doi.org/10.1186/2047-783X-14-S4-128 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20156743

17 

Ghayumi SM, Mehrabi S, Doroudchi M, Ghaderi A. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res. 2005;11:236–41. DOI: http://dx.doi.org/10.1007/BF02893857 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16388321

18 

Sahn SA. Getting the most from pleural fluid analysis. Respirology. 2012;17:270–7. DOI: http://dx.doi.org/10.1111/j.1440-1843.2011.02100.x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22059482

19 

Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398–405. DOI: http://dx.doi.org/10.1002/jcla.20208 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18022924

20 

Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a Panel of tumor Markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate Antigen 15–3, and Cytokeratin 19 Fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63. DOI: http://dx.doi.org/10.1378/chest.126.6.1757 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15596670

21 

Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298–303. DOI: http://dx.doi.org/10.1378/chest.128.4.2298 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16236887

22 

Li CS, Cheng BC, Ge W, Gao JF. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract. 2007;61:444–8. DOI: http://dx.doi.org/10.1111/j.1742-1241.2006.01111.x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/17313612

23 

Feng M, Zhu J, Liang L, Zeng N, Wu Y, Wan C, et al. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. Int J Clin Oncol. 2017;22:283–90. DOI: http://dx.doi.org/10.1007/s10147-016-1073-y PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27990560

24 

Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, et al. Diagnostic value of CYFRA 21–1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–42. DOI: http://dx.doi.org/10.1378/chest.119.4.1138 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11296181

25 

Hsu YP, Hsieh CH, Chien HT, Lai CH, Tsao CK, Liao CT, et al. Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma. World J Surg Oncol. 2015;13:253–61. DOI: http://dx.doi.org/10.1186/s12957-015-0656-9 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26292957

26 

Lee JH. Clinical usefulness of serum CYFRA 21–1 in patients with colorectal cancer. Nucl Med Mol Imaging. 2013;47:181–7. DOI: http://dx.doi.org/10.1007/s13139-013-0218-4 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24900105

27 

Isgrò MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125–43. DOI: http://dx.doi.org/10.1007/978-94-017-7215-0_9 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26530364

28 

Bottoni P, Scatena R. The Role of CA 125 as tumor Marker: Biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:229–44. DOI: http://dx.doi.org/10.1007/978-94-017-7215-0_14 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26530369

Posjeta: 81 *